AGIO Quote, Financials, Valuation and Earnings

Blueprint Medicines has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of 0.33%. Agios Pharmaceuticals's return on equity of 55.14% beat Blueprint Medicines's return on equity of -49.13%.

Agios Pharmaceuticals has a consensus price target of $51.71, signalling upside risk potential of 28.16%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -2%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Agios Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.062% less volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Agios Pharmaceuticals's net income of -$89.3M is lower than Blueprint Medicines's net income of $496K. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.59x while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 63.06x versus 14.76x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of -17.31%. Agios Pharmaceuticals's return on equity of 55.14% beat Amicus Therapeutics's return on equity of -17.7%.

Agios Pharmaceuticals has a consensus price target of $51.71, signalling upside risk potential of 28.16%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 151.48%. Given that Amicus Therapeutics has higher upside potential than Agios Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.062% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.508, suggesting its less volatile than the S&P 500 by 49.181%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Amicus Therapeutics quarterly revenues of $125.2M. Agios Pharmaceuticals's net income of -$89.3M is lower than Amicus Therapeutics's net income of -$21.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.59x while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 63.06x versus 3.54x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of -442.4%. Agios Pharmaceuticals's return on equity of 55.14% beat Sage Therapeutics's return on equity of -64.19%.

Agios Pharmaceuticals has a consensus price target of $51.71, signalling upside risk potential of 28.16%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.4%. Given that Agios Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe Agios Pharmaceuticals is more attractive than Sage Therapeutics.

Agios Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.062% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Sage Therapeutics quarterly revenues of $14.1M. Agios Pharmaceuticals's net income of -$89.3M is lower than Sage Therapeutics's net income of -$62.2M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.59x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 63.06x versus 11.79x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -1023.25% compared to Agios Pharmaceuticals's net margin of 23.33%. Agios Pharmaceuticals's return on equity of 55.14% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Agios Pharmaceuticals has a consensus price target of $51.71, signalling upside risk potential of 28.16%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that Agios Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Agios Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.729, which suggesting that the stock is 27.062% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $8.7M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Agios Pharmaceuticals's net income of -$89.3M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 3.59x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 63.06x versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.